On April 6, 2018 Sanofi reported it will present nine abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago from April 14-18 (Press release, Sanofi Genzyme, APR 6, 2018, View Source [SID1234525209]). Building on its strong heritage in oncology, the company will share new, early-stage studies highlighting an emerging and dynamic portfolio that encompasses diverse strategies, including immuno-oncology (I-O).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sanofi’s abstracts at AACR (Free AACR Whitepaper) will include a late-breaking pre-clinical presentation in partnership with BioNTech highlighting the potential impact of combination treatment with intratumoral cytokine mRNAs, an emerging class of immunotherapy medication. Additionally, results on overcoming resistance to an already-established type of immunotherapy, PD-1 (programmed cell death protein 1) inhibitors, will be presented. Notably, these data will feature Sanofi’s TGF-beta candidate, SAR439459, along with a joint presentation with Evotec on the investigational candidate EVT801, a small molecule inhibitor of VEGFR3 to target myeloid derived suppressor cells (MDSCs) in the tumor microenvironment.
Sanofi is also advancing SAR439859, a SERD (selective estrogen receptor degrader) in estrogen-receptor-positive breast cancer, and will have a number of presentations on this candidate.
"Sanofi is excited to share a broad range of promising early-stage science in oncology at AACR (Free AACR Whitepaper) 2018," said Yong-Jun Liu, M.D., Ph.D., Head of Research, Global R&D at Sanofi. "By strengthening our internal research capabilities, and by collaborating with the key therapeutic leaders in this field, we are now able to demonstrate the emerging strength and depth of our oncology pipeline at Sanofi."
The company is pursuing a breadth of approaches and new technologies to shape its early-stage oncology pipeline, including small molecule therapeutics, next-generation biologics such as antibody drug conjugates, and multi-targeting therapies.
AACR 2018 Data Presentations
Sanofi’s presentations at AACR (Free AACR Whitepaper) 2018 can be accessed via the AACR (Free AACR Whitepaper) website, and are summarized below.
Late breaking presentation
Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models (Session LBPO.IM01 – Late-Breaking Research: Immunology 1, Section 45, April 16, 2018, 8:00 AM – 12:00 PM)
Oral presentation
SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer (Session MS.EN01.01 – Novel Roles of Steroid Hormone Receptors, Room S504 – McCormick Place South (Level 5), April 15, 2018, 3:05 PM – 3:20 PM)
Sanofi presentation with Evotec
Translation to the clinic of EVT801: A novel immune-oncology agent for addressing innate-driven immunosuppression into the tumor microenvironment and expanding patient population responding to immune checkpoint therapies (PO.IM02.03 – Immune Mechanisms Invoked by Therapies 1, Section 33, April 16, 2018, 1:00 PM – 5:00 PM)
Poster presentations
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML) (Session PO.IM02.10 – Therapeutic Antibodies, Including Engineered Antibodies 1, Section 34, April 16, 2018, 8:00 AM – 12:00 PM)
Sensitivity of liver cancer cell lines to B-catenin knock-down correlates with pathway activation (Session PO.MCB03.03 – Nuclear Oncoproteins and Tumor Suppressor Genes, Section 21, April 16, 2018, 1:00 PM – 5:00 PM)
The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1 (Session PO.IM02.11 – Therapeutic Antibodies, Including Engineered Antibodies 2, Section 34, April 16, 2018, 1:00 PM – 5:00 PM)
Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer models. (Session PO.ET06.10 – Canonical Targets 2, Section 36, April 18, 2018 8:00 AM – 12:00 PM)
Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition (Session PO.MCB08.03 – Targets Affecting Metabolism Section 21, April 18, 2018, 8:00 AM – 12:00 PM)
Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy (PO.CL06.08 – Immunomodulatory Agents and Interventions 3, Section 25, April 18, 2018, 8:00 AM – 12:00 PM)
The agents identified above are under investigation only; their safety and efficacy have not been evaluated by any regulatory authority.